CA-ARIBIO
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.
“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”
AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM’s First Quantum Computer in Asia-Pacific Goes Online, Set to Open Office in Seoul13.5.2025 11:09:00 CEST | Press release
The expansion builds on IQM’s first quantum computer in the Asia-Pacific region (APAC) installed at Chungbuk National University (CBNU) in South Korea. This marks a remarkable milestone by IQM for delivering and installing the system at CBNU in four months. In fostering growth and innovation in key markets, IQM aims to advance quantum technology in Korea through collaboration with key players. With the appointment of Youngsim Kim, as country manager, the Seoul office will open in June 2025, making it IQM's second office in APAC after Singapore. IQM Quantum Computers, a global leader in superconducting quantum computers, has announced expanding its presence in Asia-Pacific with a new office opening in South Korea in June 2025, following the installation of its first quantum system at Chungbuk National University (CBNU). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513710683/en/ From left to right: Ben Lee and Mikko Välim
Ink Innovation and Riyadh Air Partner to Rethink Experience for Digital-first Travellers13.5.2025 11:06:00 CEST | Press release
Riyadh Air, the digitally native national carrier of Saudi Arabia, is joining forces with Ink Innovation to deliver a flexible and convenient air travel experience. Together, they aim to redefine standards of delivery management in a world influenced by e-commerce, cloud computing, and evolving traveller expectations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513792260/en/ Tony Douglas, CEO of Riyadh Air, said: “Ink is a key partner to Riyadh Air and continues to foster innovation at every step of the journey. As a like-minded tech-innovator, it is an ideal collaborator as we aim to provide an outstanding digital experience for our guests at their first travel touchpoint.” Moving beyond legacy systems Airlines have long struggled with outdated infrastructure—systems built to move passengers from point A to B, but not to delight or adapt. This partnership aims to change that. Riyadh Air and Ink are implementing a full
Green Street Expands Private Market Coverage with European Self-Storage Data and Analytics13.5.2025 10:00:00 CEST | Press release
Firm releases comprehensive macro insights into the European self-storage sector, via its latest Outlook report Green Street, the foremost provider of commercial real estate intelligence and insights, has expanded its private market research coverage to the European self-storage sector. Utilising 5 years of forecasted insights and 10 years of historical data, Green Street’s new Self-Storage Outlook focuses on investment opportunities available in 30 European cities. “Living quarters are becoming more compact and storage space is being cut back in urban developments, necessitating off-premises storage solutions for residential occupiers. Additionally, approximately 40% of the business customer base consists of small-to-medium-sized entities, particularly online retailers in the region,” said Marie Dormeuil, Head of European Market Analytics. “The growth in real spending on storable goods is expected to increase at 2% per annum over the next five years, supporting healthy demand growth.”
Oracle and Infobip Enhance Partnership to Deliver Global Conversational Experiences13.5.2025 10:00:00 CEST | Press release
Global cloud communications platform Infobip today announced that it has enhanced its partnership with Oracle to bring conversational experiences to businesses and brands globally. The new integration enables Infobip and Oracle customers and partners to access Infobip's omnichannel services through Oracle Integration. Customers increasingly expect omnichannel communications, but integrating and managing new channels can be time-consuming, requiring complex development, deployment, and organizational processes. Infobip’s new Omnichannel Messaging Adapter for Oracle Integration addresses this challenge byenabling all types of businesses to work with and manage omnichannel messaging channels involving Oracle and third-party solutions, including WhatsApp and RCS. The solution deploys quickly, reducing time to market. In addition, Infobip has provided a prebuilt use case – or Accelerator – for Oracle’s contact center solution, Oracle B2C Service. This Accelerator is a flexible solution that
Galeria Teams Up With Blue Yonder to Enhance the In-Store and Online Customer Shopping Experience13.5.2025 10:00:00 CEST | Press release
Germany's iconic department store chain deploys Blue Yonder’s AI-driven demand and replenishment capabilities to strengthen its commitment to quality and convenience In today's rapidly evolving retail landscape, consumers increasingly seek personalized shopping experiences tailored to meet their specific demand requirements. For omni-channel retailers, success depends on seamlessly delivering high-quality products and excellent customer service powered by advanced technology that effectively supports a demand-driven, omni-channel strategy. That is why Galeria, Germany´s leading department store chain, has chosen to deploy Blue Yonder’s demand and replenishment capabilities to strengthen its supply chain and enhance operational efficiency. This strategic investment enables the retailer to deliver a highly responsive and seamless shopping experience across both in-store and online channels, reinforcing Galeria's commitment to quality and convenience. Galeria previously relied mainly on m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom